The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Open accessAbstract
Over 50% of all human cancers lose p53 function. To evaluate the role of aggregation in cancer, we asked whether wild-type (WT) p53 and the hot-spot mutant R248Q could aggregate as amyloids under physiological conditions and whether the mutant could seed aggregation of the wild-type form. The central domains (p53C) of both constructs aggregated into a mixture of oligomers and fibrils. R248Q had a greater tendency to aggregate than WT p53. Full-length p53 aggregated into amyloid-like species that bound thioflavin T. The amyloid nature of the aggregates was demonstrated using x-ray diffraction, electron microscopy, FTIR, dynamic light scattering, cell viabilility assay, and anti-amyloid immunoassay. The x-ray diffraction pattern of the fibrillar aggregates was consistent with the typical conformation of cross β-sheet amyloid fibers with reflexions of 4.7 Å and 10 Å. A seed of R248Q p53C amyloid oligomers and fibrils accelerated the aggregation of WT p53C, a behavior typical of a prion. The R248Q mutant co-localized with amyloid-like species in a breast cancer sample, which further supported its prion-like effect. A tumor cell line containing mutant p53 also revealed massive aggregation of p53 in the nucleus. We conclude that aggregation of p53 into a mixture of oligomers and fibrils sequestrates the native protein into an inactive conformation that is typical of a prionoid. This prion-like behavior of oncogenic p53 mutants provides an explanation for the negative dominance effect and may serve as a potential target for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“Oligomers, which occur within the pathway to fibril formation, have been described as the toxic species in amyloid diseases (34, 35).”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“The most frequent p53 mutation found in cancers is the hot-spot mutationR248Q,which renders the protein unable to bind cognate DNA and exert its proper functions (15, 16).”
BackgroundCommon core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen
Sunde, M., Serpell, L. C., Bartlam, M., Fraser, P. E., Pepys, M. B., & Blake, C. C. F. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1348 · Cited by 1,707
Prion-like mechanisms in neurodegenerative diseases
Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Lai, Z., Colón, W., & Kelly, J. W. (1996) · Biochemistry · doi:10.1021/bi952501g · Cited by 574
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
The Transcellular Spread of Cytosolic Amyloids, Prions, and Prionoids
Aguzzi, A., & Rajendran, L. (2009) · Neuron · doi:10.1016/j.neuron.2009.12.016 · Cited by 473
Moll, U. M., LaQuaglia, M., Bénard, J., & Riou, G. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4407 · Cited by 427
The role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway.
Chowdary, D. R., Dermody, J. J., Jha, K. K., & Ozer, H. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1997 · Cited by 278
Amyloid Fibrils of Mammalian Prion Protein Are Highly Toxic to Cultured Cells and Primary Neurons
Novitskaya, V., Bocharova, O. V., Bronstein, I., & Baskakov, I. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511174200 · Cited by 247
Fibrillar Aggregates of the Tumor Suppressor p53 Core Domain
Ishimaru, D., Andrade, L. R., Teixeira, L. S. P., Quesado, P. A., Maiolino, L. M., Lopez, P. M., Cordeiro, Y., Costa, L. T., Heckl, W. M., Weissmüller, G., et al. (2003) · Biochemistry · doi:10.1021/bi034218k · Cited by 196
Self-citationStructure, Function, and Aggregation of the Zinc-Free Form of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2003) · Biochemistry · doi:10.1021/bi026635n · Cited by 191
Physical basis of colors seen in Congo red-stained amyloid in polarized light
Howie, A. J., Brewer, D. B., Howell, D., & Jones, A. P. (2008) · Laboratory Investigation · doi:10.1038/labinvest.3700714 · Cited by 185
Conformation-dependent antibodies target diseases of protein misfolding
Glabe, C. C. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.08.009 · Cited by 156
Tumor pH: Implications for treatment and novel drug design
Gerweck, L. E. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80043-x · Cited by 153
Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors
Levy, C. B., Stumbo, A. C., Ano Bom, A. P. D., Portari, E. A., Carneiro, Y., Silva, J. L., & De Moura-Gallo, C. V. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.017 · Cited by 144
Self-citationStructural evolution of p53, p63, and p73: Implication for heterotetramer formation
Joerger, A. C., Rajagopalan, S., Natan, E., Veprintsev, D. B., Robinson, C. V., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905867106 · Cited by 142
Nicholls, C. D., McLure, K. G., Shields, M. A., & Lee, P. W. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108815200 · Cited by 138
The client protein p53 adopts a molten globule–like state in the presence of Hsp90
Park, S. J., Borin, B. N., Martinez-Yamout, M. A., & Dyson, H. J. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2045 · Cited by 128
Ostermeyer, A. G., Runko, E., Winkfield, B., Ahn, B., & Moll, U. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15190 · Cited by 125
Silva, J. L., Vieira, T. C. R. G., Gomes, M. P. B., Bom, A. P. A., Lima, L. M. T. R., de Freitas, M. S., Ishimaru, D., Cordeiro, Y., & Foguel, D. (2009) · Accounts of Chemical Research · doi:10.1021/ar900179t · Cited by 122
Self-citationPotent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides
Kocisko, D. A., Vaillant, A., Lee, K. S., Arnold, K. M., Bertholet, N., Race, R., Olsen, E. A., Juteau, J., & Caughey, B. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1034-1044.2006 · Cited by 98
Vieira, M. N. N., Forny‐Germano, L., Saraiva, L. M., Sebollela, A. S., Martinez, A. M. B., Houzel, J., Felice, F. G. D., & Ferreira, S. T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04809.x · Cited by 96
Gomes, M. P. B., Millen, T. A., Ferreira, P. S., Cunha‐e‐Silva, N. L., Vieira, T. C. R. G., Almeida, M. S., Silva, J. L., & Cordeiro, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802102200 · Cited by 93
Self-citationUbiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression
Chen, L., Lu, W., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1999) · Molecular Medicine · doi:10.1007/bf03402136 · Cited by 79
Higashimoto, Y., Asanomi, Y., Takakusagi, S., Lewis, M. S., Uosaki, K., Durell, S. R., Anderson, C. W., Appella, E., & Sakaguchi, K. (2006) · Biochemistry · doi:10.1021/bi051192j · Cited by 75
Getting p53 Out of the Nucleus
Gottifredi, V., & Prives, C. L. (2001) · Science · doi:10.1126/science.1062238 · Cited by 68
Caughey, B. W., Caughey, W. S., Kocisko, D. A., Lee, K. S., Silveira, J. R., & Morrey, J. D. (2006) · Accounts of Chemical Research · doi:10.1021/ar050068p · Cited by 65
Cognate DNA Stabilizes the Tumor Suppressor p53 and Prevents Misfolding and Aggregation
Ishimaru, D., Bom, A. P. D. A., Lima, L. M. T. R., Quesado, P. A., Oyama, M. F. C., Gallo, C. V. D. M., Cordeiro, Y., & Silva, J. L. (2009) · Biochemistry · doi:10.1021/bi9003028 · Cited by 64
Self-citationRigacci, S., Bucciantini, M., Relini, A., Pesce, A., Gliozzi, A., Berti, A., & Stefani, M. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.122283 · Cited by 64
The two faces of Janus: functional interactions and protein aggregation
Pastore, A., & Temussi, P. A. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.11.007 · Cited by 63
The p53 Core Domain Is a Molten Globule at Low pH
Bom, A. P. D. A., de Freitas, M. S., Moreira, F. S., Ferraz, D., Sanches, D., Gomes, A. M. O., Valente, A. P., Cordeiro, Y., & Silva, J. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075861 · Cited by 61
Self-citationVieira, T. C. R. G., Reynaldo, D. P., Gomes, M. P. B., Almeida, M. S., Cordeiro, Y., & Silva, J. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106725p · Cited by 59
Self-citationReversible Aggregation Plays a Crucial Role on the Folding Landscape of p53 Core Domain
Ishimaru, D., Lima, L. M. T. R., Maia, L. F., Lopez, P. M., Bom, A. P. A., Valente, A. P., & Silva, J. L. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.044685 · Cited by 56
Self-citationPotential roles for prions and protein-only inheritance in cancer
Antony, H., Wiegmans, A. P., Wei, M.-Q., Chernoff, Y. O., Khanna, K. K., & Munn, A. L. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9325-9 · Cited by 39
The peculiar interaction between mammalian prion protein and RNA
Gomes, M. P. B., Cordeiro, Y., & Silva, J. L. (2008) · Prion · doi:10.4161/pri.2.2.6988 · Cited by 33
Self-citationGalea, C. A., Bowman, P., & Kriwacki, R. W. (2005) · Protein Science · doi:10.1110/ps.051622005 · Cited by 27
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S.-I., Merlini, G., Saraiva, M. J. M., & Westermark, P. (2016) · Amyloid · doi:10.1080/13506129.2016.1257986 · Cited by 605
The activities of amyloids from a structural perspective
Riek, R., & Eisenberg, D. S. (2016) · Nature · doi:10.1038/nature20416 · Cited by 508
Metadata
- Authors
- Ano Bom, A. P. D., Rangel, L. P., Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A., Gava, L. M., Ramos, C. H. I., Cepeda, A. O. T., Stumbo, A. C., De Moura Gallo, C. V., Cordeiro, Y., & Silva, J. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 287
- Issue
- 33
- Pages
- 28152-28162
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2132188221
- Cited by
- 280
- References
- 44
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.